Analysis of Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter - aVenture Research
Shockwave Medical
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
SANTA CLARA, Calif. – May 12, 2026 – Johnson & Johnson (NYSE: JNJ) announced today the global launch of its Shockwave C2 Aero Coronary IVL Catheter designed for improved deliverability, enhanced lesion crossing and new repositioning capabilities for the treatment of calcified coronary artery disease (CAD).1,2,3 The next-generation coronary IVL catheter leverages Shockwave IVL’s unique mechanism of action and the safety and effectiveness profile of its legacy catheters, expanding the company’s ma
An analysis reads this article and its sources, then explains what happened, who is involved, and what it means, quoting a source for each claim. Once written, every reader sees it here.
Analysis requires a paid plan or prepaid credits and uses your company research allowance.